Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Phase 1

Terminated

Conditions: Carcinoma
Ovarian Cancer
Ovarian Diseases
Ovarian Neoplasms

Interventions: Biological: AGS-8M4
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: gemcitabine
Drug: carboplatin

First Posted Date: 2009-11-18

Last Posted Date: 2013-02-27

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 4

Registration Number: NCT01016054

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Everolimus

First Posted Date: 2009-11-17

Last Posted Date: 2014-03-26

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01014351

Locations: 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hematology of SW Indiana, Evansville, Indiana, United States

and more 9 locations

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Phase 3

Terminated

Conditions: Choroid Plexus Tumors
Brain Cancer

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Drug: Vincristine
Drug: Dactinomycin
Drug: Leucovorin
Drug: Irinotecan
Drug: Doxorubicin
Drug: Methotrexate
Drug: Temozolomide

First Posted Date: 2009-11-17

Last Posted Date: 2019-08-20

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 27

Registration Number: NCT01014767

Locations: 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇭🇺
Semmelweis University, Budapest, Hungary

and more 2 locations

Merkel Positron Emission Tomography (PET) Protocol

Phase 2

Completed

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Radiation: Radiotherapy

First Posted Date: 2009-11-16

Last Posted Date: 2022-11-18

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 43

Registration Number: NCT01013779

Locations: 🇦🇺
Royal Prince Alfred, Sydney, New South Wales, Australia
🇦🇺
Royal Brisbane Hospital, Herston, Queensland, Australia
🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia

and more 10 locations

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Stage IV Breast Cancer
Breast Cancer
Recurrent Breast Cancer

Interventions: Biological: panitumumab
Drug: paclitaxel
Drug: carboplatin
Procedure: laboratory biomarker analysis
Procedure: immunohistochemistry staining method

First Posted Date: 2009-11-09

Last Posted Date: 2018-07-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 14

Registration Number: NCT01009983

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: RAD001
Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2009-11-06

Last Posted Date: 2018-07-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 9

Registration Number: NCT01009346

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: PF-01367338
Drug: Carboplatin

First Posted Date: 2009-11-06

Last Posted Date: 2023-06-08

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 85

Registration Number: NCT01009190

Locations: 🇬🇧
Churchill Hospital, Oxford, Oxfordshire, United Kingdom
🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

and more 3 locations

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Phase 2

Completed

Conditions: Stage IB Uterine Corpus Cancer AJCC v7
Stage II Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage IIIB Uterine Corpus Cancer AJCC v7
Endometrial Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2009-10-30

Last Posted Date: 2018-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01005329

Locations: 🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇺🇸
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 38 locations

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Phase 2

Completed

Conditions: Progressive Breast Cancer
Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: carboplatin
Drug: bevacizumab
Drug: herceptin

First Posted Date: 2009-10-29

Last Posted Date: 2018-12-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01004172

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Pemetrexed Disodium

First Posted Date: 2009-10-27

Last Posted Date: 2024-02-28

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 22

Registration Number: NCT01001910

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy